Cargando…
Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series
Patients undergoing hemodialysis (HD) are particularly vulnerable to coronavirus disease 2019 (COVID-19) and are at increased risk of developing severe infection. However, given the exclusion of such patients from clinical trials, there are limited data regarding the effectiveness of the antiviral d...
Autores principales: | Zhang, Ai-hua, Diao, Zong-li, Wang, Gang, Guan, Yi-ming, Liu, Ying-jie, Tian, Dong-li, Zhao, Yu-chao, Huang, Hong-dong, Liu, Wen-hu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129908/ https://www.ncbi.nlm.nih.gov/pubmed/37677996 http://dx.doi.org/10.1016/j.diagmicrobio.2023.115969 |
Ejemplares similares
-
Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023) -
483. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis
por: Li, Xin, et al.
Publicado: (2023) -
Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022) -
Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022) -
Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)